|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1974
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:atccode
|
N03 AF01
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Carbatrol
gptkb:Tegretol
gptkb:Equetro
Tegretol XR
Carbatrol ER
Equetro ER
|
|
gptkbp:casnumber
|
298-46-4
|
|
gptkbp:category
|
gptkb:D
|
|
gptkbp:chemical_formula
|
C15 H12 N2 O
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
bone marrow suppression
hypersensitivity to carbamazepine
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:discovered_by
|
1960s
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
suspension
extended-release tablet
chewable tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Carbamazepine
|
|
gptkbp:interacts_with
|
gptkb:warfarin
oral contraceptives
MAO inhibitors
|
|
gptkbp:is_monitored_by
|
gptkb:CBC
electrolytes
liver function tests
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
25 to 65 hours
|
|
gptkbp:mechanism_of_action
|
sodium channel blocker
|
|
gptkbp:metabolism
|
gptkb:CYP3_A4
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:side_effect
|
gptkb:stevens-johnson_syndrome
dizziness
nausea
drowsiness
blurred vision
liver dysfunction
cardiac arrhythmias
toxic epidermal necrolysis
hyponatremia
|
|
gptkbp:used_for
|
gptkb:epilepsy
bipolar disorder
trigeminal neuralgia
|
|
gptkbp:bfsParent
|
gptkb:Equetro
gptkb:Mavyret
|
|
gptkbp:bfsLayer
|
6
|